Home › Muscle Disorders › NCT05312424

Annatto-derived GG for Statin-associated Myopathy

Effect of Annatto-derived Geranylgeraniol (GG) on Statin-associated Myopathy

Who can join

Ages 40 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Age ≥40 of either sex
* Statin-treated patients with muscle pain alone or accompanied by other symptoms.
* Patients currently receiving a statin who developed new-onset myalgias in within 90 day of initiation or a dosage increase

Exclusion Criteria:

* Malignancy or significant neurological or psychiatric disturbances, including alcohol or drug abuse.
* Woman who is pregnant, breastfeeding, or of childbearing potential and not taking adequate contraceptive precautions.
* Had CoQ10 supplement one month before starting the study.
* Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism
* Had steroid medication one month before starting the study.

About the study

To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.

What is being tested

• Placebo (dietary supplement)
• Low GG (dietary supplement)
• High GG (dietary supplement)

Sponsor: Texas Tech University Health Sciences Center · Participants: 95 · Started: Jul 15, 2022

Contact the study team

• Chwan-Li (Leslie) Shen, PhD · Phone: 8067432815

Official record on ClinicalTrials.gov — NCT05312424

Locations in the U.S.

Conditions

• Muscle Disorders

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.